FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979330251> ?p ?o ?g. }

• W2979330251 endingPage "212" @default.
• W2979330251 startingPage "209" @default.
• W2979330251 abstract "The authors regret In the original manuscript, some studies listed on Tables 1 and 2 were not cited in the reference list. In this corrigendum, we include on the first column of Tables 1 and 2 the respective reference and provide the complete reference list (now 44 manuscripts). Also, pertinent to Table 2, we added a footnote to further clarify that data from 19 eligible studies were reported in 22 manuscripts. These corrections did not bear any effect on the results which were originally reported.Table 1Characteristics of eligible studiesAuthor, year of publication [ref]Number of patients enrolled and no. included in analysis (Gender)Median age (Range)Donor statusCell sourceConditioning regimenDisease status at time of HCTOverall survivalKato et al. 2007 8Kato K. Kanda Y. Eto T. et al.Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2007; 13: 90-99Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar33 (M = 18, F = 15)49 (24-59)MURD = 13, MMURD = 14ND = 6BM = 33MAC = 27, RIC = 6CR = 13(CR1 = 11, CR2 = 2), PR = 2, NR = 14, ND = 4OS = 49.5% (1 year)Kami et al. 2003 3Kami M. Hamaki T. Miyakoshi S. et al.Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma.British journal of haematology. 2003; 120: 304-309Crossref PubMed Scopus (80) Google Scholar11 (M = 7, F = 4)47 (15-59)MRD = 9, MMRD = 1MURD = 1BM = 7, PB = 3 PB and BM = 1MAC = 9, RIC = 2CR = 6, PR = 1, NR = 4OS = 54.5+/-30% (1 year)Ishida et al. 2012 6Ishida T. Hishizawa M. Kato K. et al.Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study.Blood. 2012; 120: 1734-1741Crossref PubMed Scopus (129) Google Scholar586 (M = 315, F = 271)53 (15-72)MRD =213, MMRD = 63MURD = 308Related with HLA typing unknown = 2BM+PB = 2, PB = 186, CB = 398MAC = 280, RIC = 306CR = 208, Non-CR = 339, Unknown = 39OS = 36% (3 year)Fukushima et al. 2011 9Fukushima T. Taguchi J. Moriuchi Y. et al.Allogeneic hematopoietic stem cell transplantation for ATL with central nervous system involvement: the Nagasaki transplant group experience.International journal of hematology. 2011; 94: 390-394Crossref PubMed Scopus (9) Google Scholar10 (M = 4, F = 6)48 (48-57)MRD-BM = 3, MRD-PB = 3MMRD-PB = 1CB = 3BM = 3, PB = 4CB = 3MAC = 6, RIC = 4CR = 1, PR = 2, NC = 2, Relapse = 1PIF = 4OS = 40% (3 year)Fukushima et al. 2005 4Fukushima T. Miyazaki Y. Honda S. et al.Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma.Leukemia. 2005; 19: 829-834Crossref PubMed Scopus (142) Google Scholar40 (M = 22, F = 18)44 (28-53)MRD = 27, MMRD = 5MURD = 8BM = 21, PB = 19MAC = 39, RIC = 1CR = 15 (CR1 = 14, CR2 = 1), PR = 13, NC = 3, PD = 9OS = 45.3% (3 year)Tanosaki et al. 2008 7Tanosaki R. Uike N. Utsunomiya A. et al.Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2008; 14: 702-708Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar14 (M = 9, F = 5)56 (50-64)MRD = 14PB = 14RIC = 14CR = 4, PR = 10OS = 36% (3 year)Okamura et al. 2005 5Okamura J. Utsunomiya A. Tanosaki R. et al.Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma.Blood. 2005; 105: 4143-4145Crossref PubMed Scopus (130) Google Scholar16 (M = 9, F = 7)57 (51-61)MRD = 16PB = 16RIC = 16Either CR or PR, number not specifiedOS = 33.3+/-12.2% (2 year)Fujiwara et al. 2017 10Fujiwara H. Fuji S. Wake A. et al.Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.Bone marrow transplantation. 2017; 52: 484-488Crossref PubMed Scopus (15) Google Scholar131*54MRD = 38, MMRD = 8MUD = 55BM = 55, PB/BM = 38CB = 30, Not classifed = 8MAC = 61, RIC = 61Missing = 9R1 = 107, R2 = 24OS = 22% (1 year)OS = 12.5% (3 year)Fuji et al. 2016 1Fuji S. Fujiwara H. Nakano N. et al.Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.Bone marrow transplantation. 2016; 51: 205-211Crossref PubMed Scopus (34) Google Scholar500*52MRD = 374, MMRD = 93Missing = 33BM = 164, PB = 336MAC = 185, RIC = 257, Missing =58CR = 161, NR = 323, Missing = 16OS = 32.5% (4 year)Yonekura et al. 2008 11Yonekura K. Utsunomiya A. Takatsuka Y. et al.Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation. 2008; 41: 1029-1035Crossref PubMed Scopus (31) Google Scholar21 (M = 13, F = 8)49 (37-62)Matched = 14, Mismatched = 7BM = 5, PB = 14, CB = 2MAC = 10, RIC = 11CR = 7, PR = 1, SD = 5, PD = 8OS = 33.2+/-10.9% (3 year)Shigmatsu et al. 2014 12Shigematsu A. Kobayashi N. Yasui H. et al.High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2014; 20: 801-805Abstract Full Text Full Text PDF PubMed Scopus (17) Google Scholar56 (M = 28, F = 28)57 (37-69)MRD = 20, MMD = 14MURD = 22BM = 39, PB = 11,CB = 6MAC = 17, RIC = 39CR = 23, Non-CR = 33OS = 55.4% (1 year)OS =46.1% (5 year)Utsunomiya et al. 2001 2Utsunomiya A. Miyazaki Y. Takatsuka Y. et al.Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation. 2001; 27: 15-20Crossref PubMed Scopus (197) Google Scholar10 (M = 7, F = 3)43 (33-51)MRD = 9, MURD =1BM = 8, PB = 1, BM+PB = 1MAC = 10CR = 4, PR = 5, NC = 1NDTokunaga et al. 2017 13Tokunaga M. Uto H. Takeuchi S. et al.Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.Leukemia & lymphoma. 2017; 58: 37-44Crossref PubMed Scopus (10) Google Scholar70 (M = 40, F = 30)52 (32-65)NDBM = 50, PB = 20MAC = 50, RIC = 20CR = 29, PR = 10, SD = 5, PD = 26OS = 35.2% (3 year)Bazarbachi et al. 2014 14Bazarbachi A. Cwynarski K. Boumendil A. et al.Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.Bone marrow transplantation. 2014; 49: 1266-1268Crossref PubMed Scopus (53) Google Scholar17 (M = 9, F = 8)47 (21-67)MRD = 6, Haploidentical = 3MURD = 7, Unknown = 1NDMAC = 4, RIC = 13CR1 = 9, PR = 4, Refractory disease = 4OS = 34.3% (3 year)Fuji et al. 2018 15Fuji S. Utsunomiya A. Inoue Y. et al.Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.Haematologica. 2018; 103: e211-e214Crossref PubMed Scopus (17) Google Scholar132*61 (25-70)MRD = 28, MMRD = 14Unrelated = 55CB = 43NDMAC = 50, RIC = 82CR = 18, PR = 29, SD = 16, PD = 68OS = 37.9% (1 year)Inoue et al. 2018 16Inoue Y. Fuji S. Tanosaki R. et al.Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.Bone marrow transplantation. 2018; 53: 1105-1115Crossref PubMed Scopus (14) Google Scholar76 (M = 35,F = 41)56 (28-69)Matched = 49, Mismatched = 27BM = 44, PB = 31CB = 1MAC = 14, RIC = 62CR = 17, PR = 29, SD = 18, PD = 12OS = 56.9% (2 year)Shiratori et al. 2008 17Shiratori S. Yasumoto A. Tanaka J. et al.A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2008; 14: 817-823Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar15 (M = 3,F = 12)57 (41-66)MRD = 10, MUD = 5BM = 8, PB = 4, PB+BM = 3MAC = 5, RIC = 10CR = 9, PR = 5, PD = 1OS = 73.3% (3 year)Kawada et al. 2015 18Kawada H. Yoshimitsu M. Nakamura D. et al.A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2015; 21: 696-700Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar29 (M = 15, F =14)55 (32-62)MRD = 5, MMD = 15MUD = 9BM = 14, PB = 14, CB = 1MAC = 2, RIC = 27CR = 10, PR = 5, SD = 1, PD = 13OS = 44.9% (3 year)Hishizawa et al. 2010 19Hishizawa M. Kanda J. Utsunomiya A. et al.Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.Blood. 2010; 116: 1369-1376Crossref PubMed Scopus (201) Google Scholar417, 386 included(M = 209, F = 177)51 (18-79)MRD = 154, MMRD = 43Unrelated = 99, CB = 90BM = 157, PB = 137, BM+PB = 2, CB = 90MAC = 114, RIC = 196CR = 118, Not CR = 246, Unknown = 22OS = 33% (3 year)M, Male; F, Female; MURD, Matched unrelated donor; MMURD, Mismatched unrelated donor; ND, Not described; MRD, Matched related donor; MMRD, Mismatched related donor; MMD, Mismatched; BM, Bone marrow; PB, Peripheral blood; CB, Cord blood; MAC, Myeloablative; RIC, Reduced intensity; CR, Complete remission; PR, Partial remission; NR, Non remission; NC, No change; PIF, Primary induction failure; PD, Progressive disease; R1, 1ST Relapse; R2, 2nd Relapse; SD, Stable disease; JSHCT, Japan Society of HCT; JMDP, Japan Marrow Donor Program. * Gender not specified Open table in a new tab Table 2Risk of bias in included studiesAuthor, year of publication [ref]Representativeness of the cohortAscertainment of exposureOutcome not present at beginningAssessment of outcomeAppropriate length of follow-upAdequacy of follow-upKato et al. 2007 8Kato K. Kanda Y. Eto T. et al.Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2007; 13: 90-99Abstract Full Text Full Text PDF PubMed Scopus (46) Google ScholarUnclearLow riskLow riskLow riskLow riskLow riskKami et al. 2003 3Kami M. Hamaki T. Miyakoshi S. et al.Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma.British journal of haematology. 2003; 120: 304-309Crossref PubMed Scopus (80) Google ScholarLow riskLow riskLow riskUnclearLow riskLow riskIshida et al. * 2012 6Ishida T. Hishizawa M. Kato K. et al.Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study.Blood. 2012; 120: 1734-1741Crossref PubMed Scopus (129) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskFukushima et al. 2011 9Fukushima T. Taguchi J. Moriuchi Y. et al.Allogeneic hematopoietic stem cell transplantation for ATL with central nervous system involvement: the Nagasaki transplant group experience.International journal of hematology. 2011; 94: 390-394Crossref PubMed Scopus (9) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskFukushima et al. 2005 4Fukushima T. Miyazaki Y. Honda S. et al.Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma.Leukemia. 2005; 19: 829-834Crossref PubMed Scopus (142) Google ScholarUnclearLow riskLow riskHigh riskLow riskLow riskTanosaki et al. 2008 7Tanosaki R. Uike N. Utsunomiya A. et al.Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2008; 14: 702-708Abstract Full Text Full Text PDF PubMed Scopus (47) Google ScholarLow riskLow riskLow riskUnclearLow riskLow riskOkamura et al. 2005 5Okamura J. Utsunomiya A. Tanosaki R. et al.Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma.Blood. 2005; 105: 4143-4145Crossref PubMed Scopus (130) Google ScholarUnclearLow riskLow riskLow riskLow riskLow riskFujiwara et al. 2017 10Fujiwara H. Fuji S. Wake A. et al.Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.Bone marrow transplantation. 2017; 52: 484-488Crossref PubMed Scopus (15) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskFuji et al. 2016 1Fuji S. Fujiwara H. Nakano N. et al.Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.Bone marrow transplantation. 2016; 51: 205-211Crossref PubMed Scopus (34) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskYonekura et al. 2008 11Yonekura K. Utsunomiya A. Takatsuka Y. et al.Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation. 2008; 41: 1029-1035Crossref PubMed Scopus (31) Google ScholarUnclearLow riskLow riskLow riskLow riskLow riskShigmatsu et al. 2014 12Shigematsu A. Kobayashi N. Yasui H. et al.High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2014; 20: 801-805Abstract Full Text Full Text PDF PubMed Scopus (17) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskIshida et al.* 2013 20Ishida T. Hishizawa M. Kato K. et al.Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2013; 19: 1731-1739Abstract Full Text Full Text PDF PubMed Scopus (37) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskKanda et al* 2012 21Kanda J. Hishizawa M. Utsunomiya A. et al.Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.Blood. 2012; 119: 2141-2148Crossref PubMed Scopus (81) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskUtsunomiya et al. 2001 2Utsunomiya A. Miyazaki Y. Takatsuka Y. et al.Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation. 2001; 27: 15-20Crossref PubMed Scopus (197) Google ScholarUnclearLow riskLow riskLow riskLow riskLow riskTokunaga et al. 2017 13Tokunaga M. Uto H. Takeuchi S. et al.Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.Leukemia & lymphoma. 2017; 58: 37-44Crossref PubMed Scopus (10) Google ScholarUnclearLow riskLow riskLow riskLow riskLow riskBazarbachi et al. 2014 14Bazarbachi A. Cwynarski K. Boumendil A. et al.Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.Bone marrow transplantation. 2014; 49: 1266-1268Crossref PubMed Scopus (53) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskFuji et al. ¥ 2018 15Fuji S. Utsunomiya A. Inoue Y. et al.Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.Haematologica. 2018; 103: e211-e214Crossref PubMed Scopus (17) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskFuji et al. ¥ 2016 22Fuji S. Inoue Y. Utsunomiya A. et al.Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2016; 34: 3426-3433Crossref PubMed Scopus (97) Google ScholarHigh riskLow riskLow riskLow riskLow riskLow riskInoue et al. 2018 16Inoue Y. Fuji S. Tanosaki R. et al.Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.Bone marrow transplantation. 2018; 53: 1105-1115Crossref PubMed Scopus (14) Google ScholarUnclearLow riskLow riskLow riskLow riskLow riskShiratori et al. 2008 17Shiratori S. Yasumoto A. Tanaka J. et al.A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2008; 14: 817-823Abstract Full Text Full Text PDF PubMed Scopus (41) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskKawada et al. 2015 18Kawada H. Yoshimitsu M. Nakamura D. et al.A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2015; 21: 696-700Abstract Full Text Full Text PDF PubMed Scopus (21) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskHishizawa et al. * 2010 19Hishizawa M. Kanda J. Utsunomiya A. et al.Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.Blood. 2010; 116: 1369-1376Crossref PubMed Scopus (201) Google ScholarLow riskLow riskLow riskLow riskLow riskLow riskFootnote: data were obtained from 22 manuscripts (19 studies).*, ¥ Manuscripts reporting overlapping cases. In some cases more than 1 manuscript could have been included because they reported on different outcomes of interest. Open table in a new tab M, Male; F, Female; MURD, Matched unrelated donor; MMURD, Mismatched unrelated donor; ND, Not described; MRD, Matched related donor; MMRD, Mismatched related donor; MMD, Mismatched; BM, Bone marrow; PB, Peripheral blood; CB, Cord blood; MAC, Myeloablative; RIC, Reduced intensity; CR, Complete remission; PR, Partial remission; NR, Non remission; NC, No change; PIF, Primary induction failure; PD, Progressive disease; R1, 1ST Relapse; R2, 2nd Relapse; SD, Stable disease; JSHCT, Japan Society of HCT; JMDP, Japan Marrow Donor Program. * Gender not specified Footnote: data were obtained from 22 manuscripts (19 studies).*, ¥ Manuscripts reporting overlapping cases. In some cases more than 1 manuscript could have been included because they reported on different outcomes of interest. The authors would like to apologise for any inconvenience caused. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1–Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-AnalysisBiology of Blood and Marrow TransplantationVol. 25Issue 8PreviewAdult T cell leukemia/lymphoma (ATLL) is a rare aggressive subtype of mature T cell neoplasms [1]. The pathogenic role of human T cell lymphotropic virus type 1 (HTLV-1) in ATLL was later elucidated, corresponding with the endemic distribution of ATLL in Japan, Central Caribbean, tropical Africa, and South America [2–4]. Four clinical subtypes have been proposed based on laboratory values and extent of clinical involvement: acute, lymphoma, chronic, and smoldering [5]. Acute and lymphoma types represent the more aggressive variants, with median survival times of 5 and 10 months, respectively [5]. Full-Text PDF Open Archive" @default.
• W2979330251 created "2019-10-18" @default.
• W2979330251 creator A5004386819 @default.
• W2979330251 creator A5008466778 @default.
• W2979330251 creator A5013468383 @default.
• W2979330251 creator A5013824370 @default.
• W2979330251 creator A5017327825 @default.
• W2979330251 creator A5023628069 @default.
• W2979330251 creator A5032928140 @default.
• W2979330251 creator A5061845933 @default.
• W2979330251 creator A5076100445 @default.
• W2979330251 date "2020-01-01" @default.
• W2979330251 modified "2023-10-09" @default.
• W2979330251 title "Corrigendum to ‘Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis’ [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]" @default.
• W2979330251 cites W1554106053 @default.
• W2979330251 cites W1972263681 @default.
• W2979330251 cites W1983701224 @default.
• W2979330251 cites W1988087661 @default.
• W2979330251 cites W1989692367 @default.
• W2979330251 cites W1991626056 @default.
• W2979330251 cites W2005501262 @default.
• W2979330251 cites W2009621572 @default.
• W2979330251 cites W2015676630 @default.
• W2979330251 cites W2022076457 @default.
• W2979330251 cites W2023755758 @default.
• W2979330251 cites W2028624655 @default.
• W2979330251 cites W2032176053 @default.
• W2979330251 cites W2074571719 @default.
• W2979330251 cites W2080959198 @default.
• W2979330251 cites W2083726156 @default.
• W2979330251 cites W2086057674 @default.
• W2979330251 cites W2094831592 @default.
• W2979330251 cites W2099464793 @default.
• W2979330251 cites W2107328434 @default.
• W2979330251 cites W2108097085 @default.
• W2979330251 cites W2117522551 @default.
• W2979330251 cites W2119092367 @default.
• W2979330251 cites W2125435699 @default.
• W2979330251 cites W2133564174 @default.
• W2979330251 cites W2136496904 @default.
• W2979330251 cites W2153245576 @default.
• W2979330251 cites W2155734807 @default.
• W2979330251 cites W2166075265 @default.
• W2979330251 cites W2261831476 @default.
• W2979330251 cites W2321606182 @default.
• W2979330251 cites W2410503019 @default.
• W2979330251 cites W2460828588 @default.
• W2979330251 cites W2505265838 @default.
• W2979330251 cites W2522908685 @default.
• W2979330251 cites W2569436233 @default.
• W2979330251 cites W2744481054 @default.
• W2979330251 cites W2785364117 @default.
• W2979330251 cites W2789917776 @default.
• W2979330251 cites W2793667135 @default.
• W2979330251 cites W2794422241 @default.
• W2979330251 doi "https://doi.org/10.1016/j.bbmt.2019.09.014" @default.
• W2979330251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31610149" @default.
• W2979330251 hasPublicationYear "2020" @default.
• W2979330251 type Work @default.
• W2979330251 sameAs 2979330251 @default.
• W2979330251 citedByCount "3" @default.
• W2979330251 countsByYear W29793302512021 @default.
• W2979330251 countsByYear W29793302512023 @default.
• W2979330251 crossrefType "journal-article" @default.
• W2979330251 hasAuthorship W2979330251A5004386819 @default.
• W2979330251 hasAuthorship W2979330251A5008466778 @default.
• W2979330251 hasAuthorship W2979330251A5013468383 @default.
• W2979330251 hasAuthorship W2979330251A5013824370 @default.
• W2979330251 hasAuthorship W2979330251A5017327825 @default.
• W2979330251 hasAuthorship W2979330251A5023628069 @default.
• W2979330251 hasAuthorship W2979330251A5032928140 @default.
• W2979330251 hasAuthorship W2979330251A5061845933 @default.
• W2979330251 hasAuthorship W2979330251A5076100445 @default.
• W2979330251 hasBestOaLocation W29793302511 @default.
• W2979330251 hasConcept C109159458 @default.
• W2979330251 hasConcept C126322002 @default.
• W2979330251 hasConcept C141071460 @default.
• W2979330251 hasConcept C143998085 @default.
• W2979330251 hasConcept C203014093 @default.
• W2979330251 hasConcept C2776913467 @default.
• W2979330251 hasConcept C2778461978 @default.
• W2979330251 hasConcept C2779338263 @default.
• W2979330251 hasConcept C2780815077 @default.
• W2979330251 hasConcept C28328180 @default.
• W2979330251 hasConcept C2911091166 @default.
• W2979330251 hasConcept C2993713153 @default.
• W2979330251 hasConcept C3017541812 @default.
• W2979330251 hasConcept C502942594 @default.
• W2979330251 hasConcept C54355233 @default.
• W2979330251 hasConcept C71924100 @default.
• W2979330251 hasConcept C86803240 @default.
• W2979330251 hasConcept C95190672 @default.
• W2979330251 hasConceptScore W2979330251C109159458 @default.
• W2979330251 hasConceptScore W2979330251C126322002 @default.
• W2979330251 hasConceptScore W2979330251C141071460 @default.
• W2979330251 hasConceptScore W2979330251C143998085 @default.
• W2979330251 hasConceptScore W2979330251C203014093 @default.
• W2979330251 hasConceptScore W2979330251C2776913467 @default.

• next